 Kathryn Colborn
Concepts (410)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electronic Health Records | 10 | 2023 | 799 | 3.010 |
Why?
| | Postoperative Complications | 29 | 2023 | 2150 | 2.500 |
Why?
| | Quality Improvement | 14 | 2023 | 953 | 1.420 |
Why?
| | Sepsis | 6 | 2023 | 509 | 1.390 |
Why?
| | Machine Learning | 7 | 2023 | 318 | 1.380 |
Why?
| | Urinary Tract Infections | 3 | 2022 | 133 | 1.360 |
Why?
| | Surgical Procedures, Operative | 5 | 2023 | 207 | 1.320 |
Why?
| | Shock, Septic | 4 | 2023 | 187 | 1.260 |
Why?
| | Malaria | 4 | 2023 | 48 | 1.150 |
Why?
| | Surgical Wound Infection | 6 | 2023 | 247 | 1.120 |
Why?
| | Pancreatic Neoplasms | 7 | 2023 | 722 | 0.910 |
Why?
| | Retrospective Studies | 43 | 2023 | 12548 | 0.860 |
Why?
| | Postoperative Hemorrhage | 2 | 2023 | 75 | 0.840 |
Why?
| | Models, Statistical | 4 | 2020 | 602 | 0.840 |
Why?
| | Malaria, Falciparum | 2 | 2018 | 25 | 0.800 |
Why?
| | Humans | 112 | 2024 | 115052 | 0.780 |
Why?
| | Artificial Intelligence | 1 | 2023 | 145 | 0.770 |
Why?
| | Plasmodium vivax | 2 | 2018 | 3 | 0.720 |
Why?
| | Malaria, Vivax | 2 | 2018 | 4 | 0.720 |
Why?
| | Pain | 2 | 2023 | 709 | 0.720 |
Why?
| | Pneumonia | 3 | 2023 | 568 | 0.670 |
Why?
| | Inpatients | 4 | 2023 | 378 | 0.650 |
Why?
| | Risk Assessment | 16 | 2023 | 2976 | 0.620 |
Why?
| | Plasmodium falciparum | 1 | 2018 | 27 | 0.600 |
Why?
| | Poisson Distribution | 1 | 2018 | 72 | 0.600 |
Why?
| | Databases, Factual | 12 | 2023 | 1132 | 0.590 |
Why?
| | Health Plan Implementation | 1 | 2019 | 132 | 0.590 |
Why?
| | Hospitalization | 6 | 2021 | 1755 | 0.580 |
Why?
| | Risk Factors | 24 | 2023 | 8642 | 0.570 |
Why?
| | Mosquito Control | 2 | 2023 | 24 | 0.550 |
Why?
| | Carcinoma, Pancreatic Ductal | 3 | 2023 | 208 | 0.530 |
Why?
| | Extracorporeal Membrane Oxygenation | 3 | 2023 | 240 | 0.510 |
Why?
| | Palliative Care | 6 | 2023 | 639 | 0.510 |
Why?
| | Mosquito Nets | 1 | 2015 | 2 | 0.510 |
Why?
| | Anopheles | 1 | 2015 | 13 | 0.500 |
Why?
| | Surgeons | 3 | 2023 | 236 | 0.480 |
Why?
| | Middle Aged | 30 | 2023 | 26831 | 0.470 |
Why?
| | Drug Prescriptions | 3 | 2021 | 239 | 0.470 |
Why?
| | Breast Neoplasms | 5 | 2023 | 1865 | 0.470 |
Why?
| | Female | 45 | 2023 | 59619 | 0.460 |
Why?
| | Patient Discharge | 2 | 2020 | 767 | 0.420 |
Why?
| | Male | 40 | 2023 | 55737 | 0.420 |
Why?
| | Adult | 29 | 2023 | 30658 | 0.420 |
Why?
| | Ambulatory Surgical Procedures | 2 | 2023 | 47 | 0.420 |
Why?
| | Hospital Mortality | 1 | 2016 | 777 | 0.410 |
Why?
| | Aged | 22 | 2023 | 19122 | 0.410 |
Why?
| | Robotic Surgical Procedures | 2 | 2024 | 86 | 0.400 |
Why?
| | Thoracic Surgery | 2 | 2023 | 105 | 0.400 |
Why?
| | Primary Health Care | 2 | 2019 | 1512 | 0.400 |
Why?
| | Algorithms | 4 | 2019 | 1489 | 0.390 |
Why?
| | Hospice and Palliative Care Nursing | 2 | 2023 | 69 | 0.390 |
Why?
| | Quality of Life | 8 | 2024 | 2360 | 0.390 |
Why?
| | Opioid-Related Disorders | 1 | 2018 | 414 | 0.370 |
Why?
| | Neoadjuvant Therapy | 6 | 2023 | 298 | 0.370 |
Why?
| | Child, Preschool | 14 | 2023 | 9093 | 0.370 |
Why?
| | Incidence | 8 | 2023 | 2318 | 0.360 |
Why?
| | Influenza, Human | 3 | 2021 | 546 | 0.360 |
Why?
| | Patient Reported Outcome Measures | 5 | 2024 | 250 | 0.350 |
Why?
| | Emergency Treatment | 2 | 2021 | 113 | 0.330 |
Why?
| | Cardiac Surgical Procedures | 2 | 2023 | 413 | 0.310 |
Why?
| | Research Design | 3 | 2022 | 930 | 0.310 |
Why?
| | Hospitals | 3 | 2022 | 582 | 0.300 |
Why?
| | Osteoarthritis, Knee | 2 | 2021 | 213 | 0.300 |
Why?
| | Logistic Models | 5 | 2023 | 1839 | 0.290 |
Why?
| | Autism Spectrum Disorder | 2 | 2023 | 322 | 0.290 |
Why?
| | Aged, 80 and over | 9 | 2023 | 6357 | 0.290 |
Why?
| | Cohort Studies | 10 | 2023 | 4904 | 0.290 |
Why?
| | Arthroplasty, Replacement, Knee | 2 | 2021 | 246 | 0.280 |
Why?
| | Chagas Disease | 2 | 2018 | 34 | 0.280 |
Why?
| | Rectal Neoplasms | 2 | 2019 | 122 | 0.280 |
Why?
| | Adenocarcinoma | 2 | 2023 | 795 | 0.270 |
Why?
| | Mass Drug Administration | 3 | 2023 | 5 | 0.270 |
Why?
| | Colorado | 7 | 2021 | 4089 | 0.270 |
Why?
| | Asthma | 1 | 2019 | 2051 | 0.260 |
Why?
| | United States | 15 | 2023 | 12227 | 0.250 |
Why?
| | Heart Defects, Congenital | 2 | 2022 | 665 | 0.250 |
Why?
| | Heart Failure | 4 | 2018 | 1962 | 0.240 |
Why?
| | Emergency Service, Hospital | 3 | 2020 | 1812 | 0.240 |
Why?
| | Young Adult | 11 | 2020 | 10498 | 0.230 |
Why?
| | Analgesics, Opioid | 3 | 2021 | 774 | 0.230 |
Why?
| | Metastasectomy | 1 | 2023 | 12 | 0.220 |
Why?
| | Predictive Value of Tests | 4 | 2022 | 1812 | 0.220 |
Why?
| | Hernia, Hiatal | 1 | 2023 | 32 | 0.220 |
Why?
| | Specialties, Surgical | 2 | 2021 | 70 | 0.220 |
Why?
| | Practice Patterns, Physicians' | 3 | 2021 | 1178 | 0.220 |
Why?
| | Endarterectomy, Carotid | 1 | 2023 | 42 | 0.220 |
Why?
| | Hypothermia | 1 | 2023 | 39 | 0.220 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2023 | 29 | 0.210 |
Why?
| | Adolescent | 13 | 2023 | 17866 | 0.210 |
Why?
| | Multivariate Analysis | 2 | 2023 | 1435 | 0.210 |
Why?
| | Europe | 1 | 2023 | 336 | 0.210 |
Why?
| | Insecticides | 1 | 2023 | 31 | 0.210 |
Why?
| | Microcephaly | 1 | 2023 | 52 | 0.210 |
Why?
| | Thoracic Surgical Procedures | 1 | 2023 | 56 | 0.210 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2023 | 60 | 0.210 |
Why?
| | MEF2 Transcription Factors | 1 | 2022 | 55 | 0.210 |
Why?
| | Risk Adjustment | 1 | 2023 | 75 | 0.210 |
Why?
| | Ischemic Attack, Transient | 1 | 2023 | 61 | 0.210 |
Why?
| | Pain, Postoperative | 2 | 2021 | 193 | 0.210 |
Why?
| | Carotid Stenosis | 1 | 2023 | 79 | 0.210 |
Why?
| | Sentinel Lymph Node | 1 | 2022 | 37 | 0.200 |
Why?
| | Telemetry | 1 | 2022 | 35 | 0.200 |
Why?
| | Polypharmacy | 1 | 2023 | 74 | 0.200 |
Why?
| | Pneumonectomy | 1 | 2023 | 125 | 0.200 |
Why?
| | Syncope | 1 | 2022 | 37 | 0.200 |
Why?
| | Medication Therapy Management | 1 | 2023 | 67 | 0.200 |
Why?
| | Chemotherapy, Adjuvant | 4 | 2023 | 332 | 0.200 |
Why?
| | Delirium | 1 | 2023 | 66 | 0.200 |
Why?
| | Neuroendocrine Tumors | 1 | 2023 | 83 | 0.200 |
Why?
| | Infant | 9 | 2023 | 7946 | 0.200 |
Why?
| | Galectins | 1 | 2022 | 22 | 0.200 |
Why?
| | Chemoradiotherapy, Adjuvant | 2 | 2019 | 40 | 0.200 |
Why?
| | Drug Hypersensitivity | 1 | 2023 | 85 | 0.200 |
Why?
| | Ivermectin | 1 | 2021 | 9 | 0.190 |
Why?
| | Preoperative Care | 2 | 2021 | 318 | 0.190 |
Why?
| | Mozambique | 2 | 2018 | 5 | 0.190 |
Why?
| | Prognosis | 7 | 2023 | 3335 | 0.190 |
Why?
| | Knee Joint | 2 | 2021 | 324 | 0.190 |
Why?
| | Mastectomy, Segmental | 1 | 2021 | 76 | 0.190 |
Why?
| | Treatment Outcome | 10 | 2023 | 9123 | 0.190 |
Why?
| | Program Evaluation | 3 | 2021 | 825 | 0.180 |
Why?
| | Intensive Care Units | 2 | 2022 | 620 | 0.180 |
Why?
| | Dysbiosis | 1 | 2022 | 146 | 0.180 |
Why?
| | Oxycodone | 1 | 2021 | 44 | 0.180 |
Why?
| | Gastric Bypass | 1 | 2022 | 93 | 0.180 |
Why?
| | New Guinea | 2 | 2018 | 4 | 0.180 |
Why?
| | Surgery Department, Hospital | 1 | 2020 | 21 | 0.180 |
Why?
| | Terminal Care | 1 | 2023 | 213 | 0.180 |
Why?
| | Arthroplasty | 1 | 2020 | 50 | 0.170 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2022 | 218 | 0.170 |
Why?
| | Zebrafish Proteins | 1 | 2022 | 246 | 0.170 |
Why?
| | Faculty | 1 | 2021 | 130 | 0.170 |
Why?
| | Anti-Anxiety Agents | 1 | 2010 | 43 | 0.170 |
Why?
| | Artemisinins | 1 | 2019 | 2 | 0.170 |
Why?
| | Hypersensitivity | 1 | 2023 | 256 | 0.170 |
Why?
| | Rural Population | 2 | 2020 | 446 | 0.170 |
Why?
| | Antimalarials | 1 | 2019 | 24 | 0.170 |
Why?
| | General Surgery | 1 | 2021 | 127 | 0.170 |
Why?
| | Venous Thromboembolism | 1 | 2023 | 231 | 0.170 |
Why?
| | Waiting Lists | 2 | 2021 | 218 | 0.170 |
Why?
| | Organ Transplantation | 1 | 2021 | 161 | 0.170 |
Why?
| | Radiotherapy, Intensity-Modulated | 2 | 2019 | 123 | 0.170 |
Why?
| | Laparoscopy | 1 | 2023 | 387 | 0.160 |
Why?
| | Anti-Infective Agents | 1 | 2022 | 225 | 0.160 |
Why?
| | Cognition | 2 | 2023 | 983 | 0.160 |
Why?
| | Prisons | 1 | 2010 | 72 | 0.160 |
Why?
| | Latent Tuberculosis | 1 | 2010 | 64 | 0.160 |
Why?
| | Child | 11 | 2023 | 18409 | 0.160 |
Why?
| | Obesity, Morbid | 1 | 2022 | 198 | 0.160 |
Why?
| | Burns | 1 | 2022 | 238 | 0.160 |
Why?
| | Induction Chemotherapy | 1 | 2019 | 56 | 0.160 |
Why?
| | Zebrafish | 1 | 2022 | 411 | 0.160 |
Why?
| | Education, Medical, Undergraduate | 1 | 2021 | 169 | 0.160 |
Why?
| | Outpatients | 1 | 2022 | 328 | 0.160 |
Why?
| | Aftercare | 1 | 2020 | 186 | 0.160 |
Why?
| | Triage | 1 | 2021 | 192 | 0.160 |
Why?
| | Defibrillators, Implantable | 1 | 2022 | 286 | 0.160 |
Why?
| | Autistic Disorder | 1 | 2020 | 161 | 0.160 |
Why?
| | Datasets as Topic | 1 | 2019 | 98 | 0.160 |
Why?
| | Condoms, Female | 1 | 2008 | 6 | 0.160 |
Why?
| | Quinolines | 1 | 2019 | 129 | 0.160 |
Why?
| | Community Participation | 1 | 2019 | 116 | 0.160 |
Why?
| | Soft Tissue Infections | 1 | 2008 | 30 | 0.150 |
Why?
| | Social Marketing | 1 | 2008 | 13 | 0.150 |
Why?
| | Hospitals, University | 1 | 2018 | 170 | 0.150 |
Why?
| | Herpesvirus 4, Human | 1 | 2019 | 125 | 0.150 |
Why?
| | Developed Countries | 1 | 2018 | 28 | 0.150 |
Why?
| | Ventricular Function | 1 | 2018 | 56 | 0.150 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 372 | 0.150 |
Why?
| | Reproductive Medicine | 1 | 2008 | 15 | 0.150 |
Why?
| | ROC Curve | 1 | 2019 | 447 | 0.150 |
Why?
| | Patient Admission | 1 | 2019 | 175 | 0.150 |
Why?
| | Computers, Handheld | 1 | 2018 | 24 | 0.150 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2019 | 72 | 0.150 |
Why?
| | Climate | 1 | 2018 | 85 | 0.150 |
Why?
| | Immunoglobulin A | 1 | 2019 | 171 | 0.150 |
Why?
| | Population Groups | 1 | 2018 | 57 | 0.150 |
Why?
| | Occupational Health | 1 | 2010 | 164 | 0.150 |
Why?
| | Geography | 1 | 2018 | 180 | 0.150 |
Why?
| | Safety-net Providers | 1 | 2019 | 95 | 0.150 |
Why?
| | Recovery of Function | 1 | 2021 | 575 | 0.150 |
Why?
| | Sentinel Lymph Node Biopsy | 3 | 2023 | 98 | 0.150 |
Why?
| | Sentinel Surveillance | 1 | 2017 | 38 | 0.150 |
Why?
| | Patient Compliance | 1 | 2021 | 524 | 0.150 |
Why?
| | Condoms | 1 | 2008 | 113 | 0.140 |
Why?
| | Substance Abuse, Intravenous | 1 | 2008 | 99 | 0.140 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 299 | 0.140 |
Why?
| | Lymph Node Excision | 3 | 2023 | 140 | 0.140 |
Why?
| | Epidemics | 1 | 2018 | 69 | 0.140 |
Why?
| | Anxiety Disorders | 1 | 2010 | 307 | 0.140 |
Why?
| | Occupational Exposure | 1 | 2010 | 256 | 0.140 |
Why?
| | Students, Medical | 1 | 2021 | 272 | 0.140 |
Why?
| | Gastroenteritis | 1 | 2017 | 65 | 0.140 |
Why?
| | Cell Phone | 1 | 2017 | 77 | 0.140 |
Why?
| | Membrane Glycoproteins | 1 | 2019 | 429 | 0.140 |
Why?
| | Influenza Vaccines | 1 | 2021 | 496 | 0.140 |
Why?
| | Nurse Practitioners | 1 | 2018 | 102 | 0.140 |
Why?
| | Mass Screening | 2 | 2020 | 1012 | 0.140 |
Why?
| | Patient Readmission | 2 | 2020 | 606 | 0.140 |
Why?
| | Melanoma | 1 | 2022 | 622 | 0.140 |
Why?
| | Radiotherapy, Conformal | 1 | 2016 | 68 | 0.130 |
Why?
| | Alcoholism | 1 | 2023 | 716 | 0.130 |
Why?
| | Forecasting | 1 | 2018 | 332 | 0.130 |
Why?
| | Fever | 1 | 2017 | 280 | 0.130 |
Why?
| | Patient Protection and Affordable Care Act | 1 | 2017 | 99 | 0.130 |
Why?
| | Healthcare Disparities | 2 | 2018 | 480 | 0.130 |
Why?
| | Atrial Fibrillation | 1 | 2020 | 325 | 0.130 |
Why?
| | Morbidity | 3 | 2022 | 279 | 0.130 |
Why?
| | Models, Organizational | 1 | 2016 | 140 | 0.130 |
Why?
| | Cannabidiol | 1 | 2016 | 60 | 0.130 |
Why?
| | Antibodies, Viral | 1 | 2019 | 522 | 0.130 |
Why?
| | Mobile Applications | 1 | 2017 | 140 | 0.130 |
Why?
| | Skin Neoplasms | 1 | 2022 | 758 | 0.130 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 1354 | 0.130 |
Why?
| | Humidity | 1 | 2015 | 37 | 0.120 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2023 | 757 | 0.120 |
Why?
| | Advance Care Planning | 1 | 2018 | 197 | 0.120 |
Why?
| | Stroke | 1 | 2023 | 1015 | 0.120 |
Why?
| | Anticonvulsants | 1 | 2016 | 178 | 0.120 |
Why?
| | Diarrhea | 3 | 2023 | 171 | 0.120 |
Why?
| | Massage | 2 | 2010 | 42 | 0.120 |
Why?
| | Environmental Exposure | 1 | 2018 | 377 | 0.120 |
Why?
| | Chronic Pain | 1 | 2018 | 210 | 0.120 |
Why?
| | Models, Biological | 1 | 2021 | 1636 | 0.120 |
Why?
| | Sensitivity and Specificity | 1 | 2018 | 1715 | 0.120 |
Why?
| | Family Practice | 1 | 2018 | 427 | 0.120 |
Why?
| | Software | 1 | 2018 | 538 | 0.110 |
Why?
| | Parasitemia | 1 | 2013 | 9 | 0.110 |
Why?
| | Indians, North American | 1 | 2009 | 570 | 0.110 |
Why?
| | Emergency Medical Services | 1 | 2021 | 587 | 0.110 |
Why?
| | Prospective Studies | 5 | 2024 | 6232 | 0.110 |
Why?
| | Myocardial Infarction | 1 | 2020 | 930 | 0.110 |
Why?
| | Research | 1 | 2016 | 395 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2023 | 1215 | 0.110 |
Why?
| | Epilepsy | 1 | 2016 | 278 | 0.100 |
Why?
| | Medicaid | 1 | 2017 | 409 | 0.100 |
Why?
| | Heart-Assist Devices | 1 | 2018 | 485 | 0.100 |
Why?
| | Temperature | 1 | 2015 | 578 | 0.100 |
Why?
| | Multicenter Studies as Topic | 2 | 2023 | 250 | 0.100 |
Why?
| | Prevalence | 3 | 2023 | 2255 | 0.100 |
Why?
| | Axilla | 2 | 2023 | 39 | 0.100 |
Why?
| | Pain Management | 2 | 2010 | 289 | 0.100 |
Why?
| | Feedback | 2 | 2023 | 146 | 0.100 |
Why?
| | Mastectomy | 2 | 2023 | 99 | 0.100 |
Why?
| | Disease Progression | 1 | 2019 | 2389 | 0.100 |
Why?
| | Patients | 2 | 2023 | 162 | 0.100 |
Why?
| | Age Factors | 4 | 2021 | 2894 | 0.100 |
Why?
| | Internship and Residency | 1 | 2021 | 941 | 0.100 |
Why?
| | Uganda | 2 | 2023 | 70 | 0.090 |
Why?
| | Lymphatic Metastasis | 2 | 2023 | 275 | 0.090 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2551 | 0.090 |
Why?
| | Time Factors | 4 | 2023 | 6142 | 0.090 |
Why?
| | Heart Transplantation | 1 | 2017 | 669 | 0.090 |
Why?
| | Antineoplastic Agents | 1 | 2021 | 1879 | 0.090 |
Why?
| | Lung Neoplasms | 1 | 2023 | 2201 | 0.090 |
Why?
| | Anti-HIV Agents | 1 | 2016 | 668 | 0.090 |
Why?
| | Laboratories | 2 | 2021 | 95 | 0.090 |
Why?
| | Postoperative Period | 2 | 2021 | 292 | 0.090 |
Why?
| | Pandemics | 3 | 2023 | 1322 | 0.090 |
Why?
| | Feeding Behavior | 1 | 2015 | 574 | 0.080 |
Why?
| | Guatemala | 2 | 2023 | 266 | 0.080 |
Why?
| | Delivery of Health Care | 1 | 2016 | 835 | 0.080 |
Why?
| | Lymph Nodes | 2 | 2023 | 422 | 0.080 |
Why?
| | Surveys and Questionnaires | 4 | 2023 | 4631 | 0.080 |
Why?
| | Seasons | 2 | 2020 | 448 | 0.080 |
Why?
| | Survival Rate | 2 | 2023 | 1646 | 0.080 |
Why?
| | Proportional Hazards Models | 2 | 2023 | 1080 | 0.080 |
Why?
| | Echocardiography | 2 | 2022 | 557 | 0.070 |
Why?
| | Comorbidity | 2 | 2022 | 1457 | 0.070 |
Why?
| | Referral and Consultation | 2 | 2023 | 633 | 0.070 |
Why?
| | Follow-Up Studies | 3 | 2021 | 4420 | 0.070 |
Why?
| | Length of Stay | 2 | 2023 | 951 | 0.070 |
Why?
| | Immunization Programs | 1 | 2009 | 206 | 0.070 |
Why?
| | Urban Population | 2 | 2020 | 401 | 0.070 |
Why?
| | School Health Services | 1 | 2009 | 206 | 0.070 |
Why?
| | Pilot Projects | 2 | 2023 | 1375 | 0.070 |
Why?
| | Affect | 1 | 2008 | 246 | 0.070 |
Why?
| | Insurance Coverage | 2 | 2017 | 201 | 0.070 |
Why?
| | Patient Satisfaction | 2 | 2021 | 580 | 0.070 |
Why?
| | Cross-Sectional Studies | 3 | 2023 | 4411 | 0.060 |
Why?
| | Infant, Newborn | 3 | 2022 | 5040 | 0.060 |
Why?
| | Body Mass Index | 2 | 2023 | 1967 | 0.060 |
Why?
| | Socioeconomic Factors | 2 | 2020 | 1081 | 0.060 |
Why?
| | Cytokines | 2 | 2023 | 1843 | 0.060 |
Why?
| | Acute Disease | 2 | 2017 | 915 | 0.060 |
Why?
| | Health Care Surveys | 2 | 2010 | 538 | 0.060 |
Why?
| | Community Health Workers | 1 | 2023 | 45 | 0.050 |
Why?
| | Anti-Bacterial Agents | 2 | 2023 | 1477 | 0.050 |
Why?
| | Herniorrhaphy | 1 | 2023 | 49 | 0.050 |
Why?
| | Multilocus Sequence Typing | 1 | 2022 | 12 | 0.050 |
Why?
| | Health Facilities | 1 | 2023 | 72 | 0.050 |
Why?
| | Sternotomy | 1 | 2022 | 18 | 0.050 |
Why?
| | Growth Disorders | 1 | 2023 | 78 | 0.050 |
Why?
| | Death | 1 | 2023 | 109 | 0.050 |
Why?
| | Biological Variation, Population | 1 | 2022 | 19 | 0.050 |
Why?
| | Vomiting | 1 | 2023 | 124 | 0.050 |
Why?
| | Body Surface Area | 1 | 2022 | 27 | 0.050 |
Why?
| | Burn Units | 1 | 2022 | 26 | 0.050 |
Why?
| | Breast | 1 | 2023 | 139 | 0.050 |
Why?
| | Papua New Guinea | 1 | 2012 | 7 | 0.050 |
Why?
| | Cough | 1 | 2023 | 107 | 0.050 |
Why?
| | HIV Infections | 1 | 2016 | 2470 | 0.050 |
Why?
| | Patient Acuity | 1 | 2022 | 42 | 0.050 |
Why?
| | Carotid Arteries | 1 | 2023 | 183 | 0.050 |
Why?
| | Neutrophil Infiltration | 1 | 2022 | 94 | 0.050 |
Why?
| | Disease-Free Survival | 1 | 2023 | 617 | 0.050 |
Why?
| | Neurosurgical Procedures | 1 | 2023 | 154 | 0.050 |
Why?
| | Pancreatectomy | 1 | 2023 | 169 | 0.050 |
Why?
| | Focus Groups | 1 | 2023 | 385 | 0.050 |
Why?
| | Diagnostic Tests, Routine | 1 | 2022 | 87 | 0.050 |
Why?
| | Educational Status | 1 | 2023 | 412 | 0.050 |
Why?
| | Inappropriate Prescribing | 1 | 2022 | 52 | 0.050 |
Why?
| | Gastrectomy | 1 | 2022 | 83 | 0.050 |
Why?
| | Demography | 1 | 2022 | 261 | 0.050 |
Why?
| | Sample Size | 1 | 2021 | 112 | 0.050 |
Why?
| | Lung | 2 | 2024 | 3595 | 0.050 |
Why?
| | Receptor, ErbB-2 | 1 | 2023 | 300 | 0.050 |
Why?
| | Animals | 3 | 2022 | 31868 | 0.050 |
Why?
| | Ligands | 1 | 2023 | 565 | 0.050 |
Why?
| | Habits | 1 | 2020 | 37 | 0.050 |
Why?
| | Preoperative Period | 1 | 2021 | 103 | 0.050 |
Why?
| | Chemoradiotherapy | 1 | 2022 | 187 | 0.050 |
Why?
| | Research Personnel | 1 | 2022 | 151 | 0.050 |
Why?
| | Fear | 1 | 2023 | 292 | 0.050 |
Why?
| | Reoperation | 1 | 2023 | 519 | 0.050 |
Why?
| | Censuses | 1 | 2020 | 18 | 0.040 |
Why?
| | South Africa | 1 | 2021 | 161 | 0.040 |
Why?
| | Schools, Medical | 1 | 2021 | 122 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2023 | 1127 | 0.040 |
Why?
| | Policy | 1 | 2021 | 138 | 0.040 |
Why?
| | Emergencies | 1 | 2021 | 147 | 0.040 |
Why?
| | Blood Proteins | 1 | 2022 | 233 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2021 | 458 | 0.040 |
Why?
| | Elective Surgical Procedures | 1 | 2021 | 152 | 0.040 |
Why?
| | Neoplasm Staging | 1 | 2023 | 1169 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2020 | 218 | 0.040 |
Why?
| | Mentors | 1 | 2021 | 158 | 0.040 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2019 | 40 | 0.040 |
Why?
| | Societies, Medical | 1 | 2023 | 678 | 0.040 |
Why?
| | Urination Disorders | 1 | 2019 | 11 | 0.040 |
Why?
| | Epstein-Barr Virus Nuclear Antigens | 1 | 2019 | 8 | 0.040 |
Why?
| | Organoplatinum Compounds | 1 | 2019 | 37 | 0.040 |
Why?
| | Leucovorin | 1 | 2019 | 42 | 0.040 |
Why?
| | Risk | 1 | 2022 | 815 | 0.040 |
Why?
| | Program Development | 1 | 2021 | 346 | 0.040 |
Why?
| | Overweight | 1 | 2023 | 474 | 0.040 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 498 | 0.040 |
Why?
| | Survivors | 1 | 2022 | 410 | 0.040 |
Why?
| | Inflammation Mediators | 1 | 2022 | 476 | 0.040 |
Why?
| | Kenya | 1 | 2019 | 98 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2020 | 331 | 0.040 |
Why?
| | Drug Combinations | 1 | 2019 | 287 | 0.040 |
Why?
| | Cardiovascular Nursing | 1 | 2018 | 3 | 0.040 |
Why?
| | Washington | 1 | 2008 | 133 | 0.040 |
Why?
| | Fluorouracil | 1 | 2019 | 152 | 0.040 |
Why?
| | Colombia | 1 | 2018 | 36 | 0.040 |
Why?
| | Guidelines as Topic | 1 | 2010 | 245 | 0.040 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2019 | 139 | 0.040 |
Why?
| | Range of Motion, Articular | 1 | 2020 | 356 | 0.040 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2023 | 856 | 0.040 |
Why?
| | Patient-Centered Care | 1 | 2023 | 474 | 0.040 |
Why?
| | Rectum | 1 | 2019 | 150 | 0.040 |
Why?
| | Hospitals, Veterans | 1 | 2009 | 244 | 0.040 |
Why?
| | Coinfection | 1 | 2019 | 120 | 0.040 |
Why?
| | Mortality | 1 | 2019 | 287 | 0.040 |
Why?
| | Mental Health | 1 | 2023 | 559 | 0.040 |
Why?
| | Weight Loss | 1 | 2022 | 642 | 0.040 |
Why?
| | Odds Ratio | 1 | 2010 | 957 | 0.040 |
Why?
| | Viral Load | 1 | 2019 | 405 | 0.040 |
Why?
| | Models, Theoretical | 1 | 2021 | 517 | 0.040 |
Why?
| | Proctitis | 1 | 2016 | 5 | 0.030 |
Why?
| | Anxiety | 1 | 2023 | 845 | 0.030 |
Why?
| | Prosthesis Design | 1 | 2018 | 285 | 0.030 |
Why?
| | Population Surveillance | 1 | 2019 | 392 | 0.030 |
Why?
| | Urogenital System | 1 | 2016 | 18 | 0.030 |
Why?
| | Latin America | 1 | 2016 | 69 | 0.030 |
Why?
| | Prisoners | 1 | 2008 | 124 | 0.030 |
Why?
| | Sexually Transmitted Diseases | 1 | 2008 | 154 | 0.030 |
Why?
| | Radiotherapy Dosage | 1 | 2016 | 244 | 0.030 |
Why?
| | Medically Uninsured | 1 | 2017 | 121 | 0.030 |
Why?
| | Guideline Adherence | 1 | 2010 | 492 | 0.030 |
Why?
| | Health Status | 1 | 2021 | 722 | 0.030 |
Why?
| | Radiation Injuries | 1 | 2016 | 127 | 0.030 |
Why?
| | Public Health | 1 | 2019 | 435 | 0.030 |
Why?
| | Self Care | 1 | 2018 | 351 | 0.030 |
Why?
| | Curriculum | 1 | 2021 | 843 | 0.030 |
Why?
| | Electrocardiography | 1 | 2018 | 562 | 0.030 |
Why?
| | Plant Extracts | 1 | 2016 | 154 | 0.030 |
Why?
| | Neoplasms | 1 | 2008 | 2106 | 0.030 |
Why?
| | Hemorrhage | 1 | 2019 | 618 | 0.030 |
Why?
| | Insurance, Health | 1 | 2017 | 244 | 0.030 |
Why?
| | Phenotype | 1 | 2022 | 2815 | 0.030 |
Why?
| | Transcription Factors | 1 | 2022 | 1531 | 0.030 |
Why?
| | Administration, Oral | 1 | 2016 | 730 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 776 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 814 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2020 | 3015 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2021 | 2799 | 0.030 |
Why?
| | Vaccination | 1 | 2021 | 1205 | 0.030 |
Why?
| | Sex Factors | 1 | 2018 | 1721 | 0.030 |
Why?
| | Communication | 1 | 2018 | 744 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2010 | 1399 | 0.030 |
Why?
| | Health Promotion | 1 | 2008 | 686 | 0.020 |
Why?
| | Biomarkers | 1 | 2022 | 3419 | 0.020 |
Why?
| | Inflammation | 1 | 2022 | 2485 | 0.020 |
Why?
| | Registries | 1 | 2018 | 1763 | 0.020 |
Why?
| | Obesity | 1 | 2023 | 2524 | 0.020 |
Why?
| | Veterans | 1 | 2009 | 1238 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2008 | 258 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2009 | 765 | 0.010 |
Why?
|
|
Colborn's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|